Literature DB >> 25077923

The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies.

Sheng-Wen Wu1, Cong-Chao Ma, Yu Yang.   

Abstract

Human epidermal growth factor receptor (HER-2/neu) plays an important role in the progression of several types of cancer. Numerous studies examining the relationship between HER-2 overexpression and prognostic impact in patients with colorectal cancer have yielded inconclusive results. We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic value of HER-2 expression on the survival, which compared the positive and negative expressions of HER-2 in patients of the available studies. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were pooled in terms of disease-specific or overall survival. A detailed search was made in PubMed for relevant original articles published in English. Finally, a total of 18 studies with 16 colorectal cancer patients were involved. Overexpression of HER-2 was negatively related to survival in colorectal cancer patients with the pooled HR of 1.05 (95% CI 0.78-1.31, P = 0.000). In conclusion, the finding from this present meta-analysis suggested that HER-2 overexpression was not related to poor prognostic of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25077923     DOI: 10.1007/s13277-014-2376-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  Colorectal cancer in Guangdong Province of China: a demographic and anatomic survey.

Authors:  An-Gao Xu; Zhi-Jin Yu; Bo Jiang; Xin-Ying Wang; Xu-Hui Zhong; Ji-Hong Liu; Qiu-Yun Lou; Ai-Hua Gan
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

5.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Frequency of HER-2 positivity in rectal cancer and prognosis.

Authors:  Lena-Christin Conradi; Hanna Styczen; Thilo Sprenger; Hendrik A Wolff; Claus Rödel; Manuel Nietert; Kia Homayounfar; Jochen Gaedcke; Julia Kitz; Recca Talaulicar; Heinz Becker; Michael Ghadimi; Peter Middel; Tim Beissbarth; Josef Rüschoff; Torsten Liersch
Journal:  Am J Surg Pathol       Date:  2013-04       Impact factor: 6.394

8.  Prognostic role of CD133 expression in colorectal cancer: a meta-analysis.

Authors:  Ke Wang; Jianjun Xu; Junshu Zhang; Jian Huang
Journal:  BMC Cancer       Date:  2012-12-05       Impact factor: 4.430

9.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

10.  The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.

Authors:  P de Graeff; A P G Crijns; K A Ten Hoor; H G Klip; H Hollema; K Oien; J M Bartlett; G B A Wisman; G H de Bock; E G E de Vries; S de Jong; A G J van der Zee
Journal:  Br J Cancer       Date:  2008-07-22       Impact factor: 7.640

View more
  6 in total

1.  HER2 expression in gastric and oesophageal cancer: a meta-analytic review.

Authors:  Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2015-04

2.  Expression of COX-2 and HER-2 in colorectal cancer and their correlation.

Authors:  Qi-Bing Wu; Guo-Ping Sun
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Correlation of human epidermal growth factor receptor protein expression and colorectal cancer.

Authors:  Wen-Juan Yang; Xing-Jie Shen; Xiao-Xia Ma; Zhi-Gang Tan; Yan Song; Yi-Tong Guo; Mei Yuan
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

4.  Association of HER2 codon 655 polymorphism with ovarian cancer.

Authors:  Rafał Watrowski; Dan Cacsire Castillo-Tong; Eva Schuster; Michael B Fischer; Paul Speiser; Robert Zeillinger
Journal:  Tumour Biol       Date:  2015-12-14

5.  HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Authors:  Hanna Styczen; Iris Nagelmeier; Tim Beissbarth; Manuel Nietert; Kia Homayounfar; Thilo Sprenger; Ute Boczek; Kathrin Stanek; Julia Kitz; Hendrik A Wolff; B Michael Ghadimi; Peter Middel; Torsten Liersch; Josef Rüschoff; Lena-Christin Conradi
Journal:  Oncotarget       Date:  2015-06-20

Review 6.  HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.

Authors:  Nicola Fusco; Silvano Bosari
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.